The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancer

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2149-2160

  Kang, Yun Hee ^a   Han, Seung Ro ^b   Kim, Jong Tae ^a   Lee, Seon Jin ^a   Yeom, Young Il ^a   Min, Jeong Ki ^a   Lee, Chul Ho ^a   Kim, Jae Wha ^a   Yoon, Suk Ran ^a   Yoon, Do Young ^c   Hong, Kwan Soo ^d   Hwang, Geum Sook ^d   Kim, Hee Cheol ^e   Lee, Young Ha ^f   Lee, Hee Gu ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Daejeon University   (South Korea)

^c Konkuk University   (South Korea)

^d Korea Basic Science Institute (KBSI)   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Chungnam National University   (South Korea)

Author keywords

Cell growth; Colorectal cancer; NF B; Tescalcin; Tumor growth

Indexed keywords

CALCIUM BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TESCALCIN; UNCLASSIFIED DRUG; TSC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; ADENOCARCINOMA; AGED; ANIMAL; COLORECTAL TUMOR; CONFOCAL MICROSCOPY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NUDE MOUSE; PATHOLOGY; WESTERN BLOTTING; XENOGRAFT;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84899581744     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1851     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-130.
2. Francipane MG and Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget. 2013; 4(11):1948-1962.
3. Cheadle EJ, Riyad K, Subar D, Rothwell DG, Ashton G, Batha H, Sherlock DJ, Hawkins RE and Gilham DE. Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res. 2007; 13(19):5719-5728.
4. Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim JT, Kim BY, Lee SJ, Choe YK, Kim DH, Kim SH, Chae SW, Kim KD and Lee HG. Collagen Triple Helix Repeat Containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget. 2014; 5(2): 519-529.
5. Chau NM and Ashcroft M. Akt2: a role in breast cancer metastasis. Breast Cancer Res. 2004; 6(1):55-57.
6. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004; 6(3):203-208.
7. Orlowski RZ and Baldwin AS, Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002; 8(8):385-389.
8. Horst D, Budczies J, Brabletz T, Kirchner T and Hlubek F. Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer. 2009; 115(21):4946-4958.
9. Basseres DS and Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006; 25(51):6817-6830.
10. Bubici C, Papa S, Pham CG, Zazzeroni F and Franzoso G. The NF-kappaB-mediated control of ROS and JNK signaling. Histol Histopathol. 2006; 21(1):69-80.
11. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U and Van Waes C. Expression of a dominantnegative mutant inhibitor-kappaBalpha of nuclear factorkappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 1999; 59(14):3468-3474.
12. Perera EM, Martin H, Seeherunvong T, Kos L, Hughes IA, Hawkins JR and Berkovitz GD. Tescalcin, a novel gene encoding a putative EF-hand Ca(2+)-binding protein, Col9a3, and renin are expressed in the mouse testis during the early stages of gonadal differentiation. Endocrinology. 2001; 142(1):455-463.
13. Levay K and Slepak VZ. Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression. J Clin Invest. 2007; 117(9):2672-2683.
14. Gutierrez-Ford C, Levay K, Gomes AV, Perera EM, Som T, Kim YM, Benovic JL, Berkovitz GD and Slepak VZ. Characterization of tescalcin, a novel EF-hand protein with a single Ca2+-binding site: metal-binding properties, localization in tissues and cells, and effect on calcineurin. Biochemistry. 2003; 42(49):14553-14565.
15. Bao Y, Hudson QJ, Perera EM, Akan L, Tobet SA, Smith CA, Sinclair AH and Berkovitz GD. Expression and evolutionary conservation of the tescalcin gene during development. Gene Expr Patterns. 2009; 9(5):273-281.
16. Li X, Liu Y, Kay CM, Muller-Esterl W and Fliegel L. The Na+/H+ exchanger cytoplasmic tail: structure, function, and interactions with tescalcin. Biochemistry. 2003; 42(24):7448-7456.
17. Mailander J, Muller-Esterl W and Dedio J. Human homolog of mouse tescalcin associates with Na(+)/H(+) exchanger type-1. FEBS Lett. 2001; 507(3):331-335.
18. Zaun HC, Shrier A and Orlowski J. Calcineurin B homologous protein 3 promotes the biosynthetic maturation, cell surface stability, and optimal transport of the Na+/H+ exchanger NHE1 isoform. J Biol Chem. 2008; 283(18):12456-12467.
19. Li X, Ding J, Liu Y, Brix BJ and Fliegel L. Functional analysis of acidic amino acids in the cytosolic tail of the Na+/H+ exchanger. Biochemistry. 2004; 43(51):16477- 16486.
20. Lin X, Sikkink RA, Rusnak F and Barber DL. Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein. J Biol Chem. 1999; 274(51):36125- 36131.
21. Pang T, Su X, Wakabayashi S and Shigekawa M. Calcineurin homologous protein as an essential cofactor for Na+/H+ exchangers. J Biol Chem. 2001; 276(20):17367- 17372.
22. Pang T, Wakabayashi S and Shigekawa M. Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger. J Biol Chem. 2002; 277(46):43771-43777.
23. Fliegel L, Sardet C, Pouyssegur J and Barr A. Identification of the protein and cDNA of the cardiac Na+/H+ exchanger. FEBS Lett. 1991; 279(1):25-29.
24. Grinstein S, Woodside M, Waddell TK, Downey GP, Orlowski J, Pouyssegur J, Wong DC and Foskett JK. Focal localization of the NHE-1 isoform of the Na+/H+ antiport: assessment of effects on intracellular pH. Embo J. 1993; 12(13):5209-5218.
25. Wakabayashi S, Pang T, Su X and Shigekawa M. A novel topology model of the human Na(+)/H(+) exchanger isoform 1. J Biol Chem. 2000; 275(11):7942-7949.
26. Kapus A, Grinstein S, Wasan S, Kandasamy R and Orlowski J. Functional characterization of three isoforms of the Na+/H+ exchanger stably expressed in Chinese hamster ovary cells. ATP dependence, osmotic sensitivity, and role in cell proliferation. J Biol Chem. 1994; 269(38):23544- 23552.
27. Rao GN, Sardet C, Pouyssegur J and Berk BC. Na+/H+ antiporter gene expression increases during retinoic acidinduced granulocytic differentiation of HL60 cells. J Cell Physiol. 1992; 151(2):361-366.
28. Kaplan DL and Boron WF. Long-term expression of c-H-ras stimulates Na-H and Na(+)-dependent Cl-HCO3 exchange in NIH-3T3 fibroblasts. J Biol Chem. 1994; 269(6):4116- 4124.
29. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999; 18(49):6853-6866.
30. Osborn L, Kunkel S and Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A. 1989; 86(7):2336-2340.
31. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005; 94:29-86.
32. Vivanco I and Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501.
33. Saturno G, Valenti M, De Haven Brandon A, Thomas GV, Eccles S, Clarke PA and Workman P. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget. 2013; 4(8):1185-1198.
34. Craven RJ, Lightfoot H and Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol. 2003; 12(1):39-49.
35. Diehl JA, Cheng M, Roussel MF and Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998; 12(22):3499- 3511.
36. Embi N, Rylatt DB and Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980; 107(2):519-527.
37. Peifer M, Pai LM and Casey M. Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase. Dev Biol. 1994; 166(2):543-556.
38. Sun T, Rodriguez M and Kim L. Glycogen synthase kinase 3 in the world of cell migration. Dev Growth Differ. 2009; 51(9):735-742.
39. Ji NY, Kim YH, Jang YJ, Kang YH, Lee CI, Kim JW, Yeom YI, Chun HK, Choi YH, Kim JH, Lee HG and Song EY. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci. 2010; 101(10):2248-2253.
40. Kim JT, Song EY, Chung KS, Kang MA, Kim JW, Kim SJ, Yeom YI, Kim JH, Kim KH and Lee HG. Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer. 2011; 117(12):2608-2619.
41. Kang YH, Ji NY, Han SR, Lee CI, Kim JW, Yeom YI, Kim YH, Chun HK, Chung JW, Ahn DK, Lee HG and Song EY. ESM-1 regulates cell growth and metastatic process through activation of NF-kappaB in colorectal cancer. Cell Signal. 2012; 24(10):1940-1949.
42. Kang YH, Park MY, Yoon DY, Han SR, Lee CI, Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, Jang YJ, Ahn DK and Song EY. Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett. 2012; 318(2):226-233.